<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">35131658</PMID><DateCompleted><Year>2022</Year><Month>02</Month><Day>18</Day></DateCompleted><DateRevised><Year>2023</Year><Month>05</Month><Day>16</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1950-6007</ISSN><JournalIssue CitedMedium="Internet"><Volume>147</Volume><PubDate><Year>2022</Year><Month>Mar</Month></PubDate></JournalIssue><Title>Biomedicine &amp; pharmacotherapy = Biomedecine &amp; pharmacotherapie</Title><ISOAbbreviation>Biomed Pharmacother</ISOAbbreviation></Journal><ArticleTitle>Antiviral effects of azithromycin: A narrative review.</ArticleTitle><Pagination><StartPage>112682</StartPage><MedlinePgn>112682</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.biopha.2022.112682</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0753-3322(22)00070-1</ELocationID><Abstract><AbstractText>Viral infections have a great impact on human health. The urgent need to find a cure against different viruses led us to investigations in a vast range of drugs. Azithromycin (AZT), classified as a macrolide, showed various effects on different known viruses such as severe acute respiratory syndrome coronavirus (SARS-CoV), Zika, Ebola, Enterovirus (EVs) and Rhinoviruses (RVs), and Influenza A previously; namely, these viruses, which caused global concerns, are considered as targets for AZT different actions. Due to AZT background in the treatment of known viral infections mentioned above (which is described in this study), in the early stages of COVID-19 (a new zoonotic disease caused by a novel coronavirus called severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)) development, AZT drew attention to itself due to its antiviral and immunomodulatory effects as a valuable candidate for COVID-19 treatment. AZT usage instructions for treating different viral infections have always been under observation, and COVID-19 is no exception. There are still debates about the use of AZT in COVID-19 treatment. However, eventually, novel researches convinced WHO to announce the discontinuation of AZT use (alone or in combination with hydroxychloroquine) in treating SARS-CoV-2 infection. This research aims to study the structure of all of the viruses mentioned above and the molecular and clinical effects of AZT against the virus.</AbstractText><CopyrightInformation>Copyright © 2022 The Authors. Published by Elsevier Masson SAS.. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Khoshnood</LastName><ForeName>Saeed</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Clinical Microbiology Research Center, Ilam University of Medical Sciences, Ilam, Iran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shirani</LastName><ForeName>Maryam</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Toxicology Research Center, Medical Basic Sciences Research Institute, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dalir</LastName><ForeName>Amine</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Microbiology, Faculty of Medicine, Iran University of Medical Sciences, Tehran, Iran; Medical Complex Clinical Research Development Center (RCRDC), Iran University of Medical Sciences, Tehran, Iran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Moradi</LastName><ForeName>Melika</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Microbiology, School of Medicine, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Haddadi</LastName><ForeName>Mohammad Hossein</ForeName><Initials>MH</Initials><AffiliationInfo><Affiliation>Clinical Microbiology Research Center, Ilam University of Medical Sciences, Ilam, Iran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sadeghifard</LastName><ForeName>Nourkhoda</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Clinical Microbiology Research Center, Ilam University of Medical Sciences, Ilam, Iran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Birjandi</LastName><ForeName>Faezeh Sabet</ForeName><Initials>FS</Initials><AffiliationInfo><Affiliation>Department of Microbiology and Virology, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yashmi</LastName><ForeName>Ilya</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Cellular and Molecular Research Center, Sabzevar University of Medical Sciences, Sabzevar, Iran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Heidary</LastName><ForeName>Mohsen</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Cellular and Molecular Research Center, Sabzevar University of Medical Sciences, Sabzevar, Iran; Department of Laboratory Sciences, School of Paramedical Sciences, Sabzevar University of Medical Sciences, Sabzevar, Iran. Electronic address: mohsenheidary40@gmail.com.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>02</Month><Day>04</Day></ArticleDate></Article><MedlineJournalInfo><Country>France</Country><MedlineTA>Biomed Pharmacother</MedlineTA><NlmUniqueID>8213295</NlmUniqueID><ISSNLinking>0753-3322</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000900">Anti-Bacterial Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>83905-01-5</RegistryNumber><NameOfSubstance UI="D017963">Azithromycin</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000900" MajorTopicYN="N">Anti-Bacterial Agents</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017963" MajorTopicYN="N">Azithromycin</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D029043" MajorTopicYN="N">Ebolavirus</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009980" MajorTopicYN="N">Influenza A virus</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D045473" MajorTopicYN="N">Severe acute respiratory syndrome-related coronavirus</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000071244" MajorTopicYN="N">Zika Virus</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000093485" MajorTopicYN="Y">COVID-19 Drug Treatment</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Azithromycin</Keyword><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">Ebola</Keyword><Keyword MajorTopicYN="N">Enterovirus and Rhinoviruses</Keyword><Keyword MajorTopicYN="N">Influenza A</Keyword><Keyword MajorTopicYN="N">SARS-CoV</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword><Keyword MajorTopicYN="N">Viral infections</Keyword><Keyword MajorTopicYN="N">Zika</Keyword></KeywordList><CoiStatement>Authors declare that they have no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>11</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>1</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>1</Month><Day>31</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>2</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>2</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>2</Month><Day>8</Day><Hour>5</Hour><Minute>46</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>2</Month><Day>4</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35131658</ArticleId><ArticleId IdType="pmc">PMC8813546</ArticleId><ArticleId IdType="doi">10.1016/j.biopha.2022.112682</ArticleId><ArticleId IdType="pii">S0753-3322(22)00070-1</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>M.W. Taylor, What is a virus? Viruses and man: a history of interactions, 2014, 23–40.</Citation></Reference><Reference><Citation>Coronavirus Cases 2021, Available from: 〈https://www.worldometers.info/coronavirus/coronavirus-cases/〉.</Citation></Reference><Reference><Citation>Ohimain E.I., Silas-Olu D. The 2013–2016 Ebola virus disease outbreak in West Africa. Curr. Opin. Pharmacol. 2021;60:360–365.</Citation><ArticleIdList><ArticleId IdType="pubmed">34537503</ArticleId></ArticleIdList></Reference><Reference><Citation>Cherry J.D. The chronology of the 2002–2003 SARS mini pandemic. Paediatr. Respir. Rev. 2004;5(4):262–269.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7106085</ArticleId><ArticleId IdType="pubmed">15531249</ArticleId></ArticleIdList></Reference><Reference><Citation>G.M. Bright, J.R. Hauske Azahomoerythromycin D derivative and intermediates therefor. United States patent US 4,465,674, 1984, Aug 14.</Citation></Reference><Reference><Citation>G. Kobrehel , G. Radobolja , Z. Tamburasev , S. Djokic 11-Aza-10-deoxo-10-dihydroerythromycin A and derivatives thereof as well as a process for their preparation. Google Patents, 1982, May 4.</Citation></Reference><Reference><Citation>Oliver M.E., Hinks T.S.C. Azithromycin in viral infections. Rev. Med. Virol. 2021;31(2)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7536932</ArticleId><ArticleId IdType="pubmed">32969125</ArticleId></ArticleIdList></Reference><Reference><Citation>Labella A.M., Merel S.E. Influenza. Med. Clin. North Am. 2013;97(4):621–645. (x)</Citation><ArticleIdList><ArticleId IdType="pubmed">23809717</ArticleId></ArticleIdList></Reference><Reference><Citation>Krammer F., Smith G.J.D., Fouchier R.A.M., Peiris M., Kedzierska K., Doherty P.C., Palese P., Shaw M.L., Treanor J., Webster R.G., García-Sastre A. Influenza. Nat. Rev. Dis. Prim. 2018;4(1):3.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7097467</ArticleId><ArticleId IdType="pubmed">29955068</ArticleId></ArticleIdList></Reference><Reference><Citation>Min J.-Y., Jang Y.J. Macrolide therapy in respiratory viral infections. Mediat. Inflamm. 2012;2012:2012.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3375106</ArticleId><ArticleId IdType="pubmed">22719178</ArticleId></ArticleIdList></Reference><Reference><Citation>Du X., Zuo X., Meng F., Han C., Ouyang W., Han Y., Gu Y., Zhao X., Xu F., Qin F.X. Direct inhibitory effect on viral entry of influenza A and SARS‐CoV‐2 viruses by azithromycin. Cell Prolif. 2021;54(1)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7744835</ArticleId><ArticleId IdType="pubmed">33211371</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee N., Wong C.-K., Chan M., Yeung E., Tam W., Tsang O., Choi K.W., Chan P., Kwok A., Lui G., Leung W.S., Yung I., Wong R., Cheung C., Hui D. Anti-inflammatory effects of adjunctive macrolide treatment in adults hospitalized with influenza: a randomized controlled trial. Antivir. Res. 2017;144:48–56.</Citation><ArticleIdList><ArticleId IdType="pubmed">28535933</ArticleId></ArticleIdList></Reference><Reference><Citation>Tran D.H., Sugamata R., Hirose T., Suzuki S., Noguchi Y., Sugawara A., Ito F., Yamamoto T., Kawachi S., Akagawa K.S., Ōmura S., Sunazuka T., Ito N., Mimaki M., Suzuki K. Azithromycin, a 15-membered macrolide antibiotic, inhibits influenza A (H1N1) pdm09 virus infection by interfering with virus internalization process. J. Antibiot. Res. 2019;72(10):759–768.</Citation><ArticleIdList><ArticleId IdType="pubmed">31300721</ArticleId></ArticleIdList></Reference><Reference><Citation>Fage C., Pizzorno A., Rhéaume C., Abed Y., Boivin G. The combination of oseltamivir with azithromycin does not show additional benefits over oseltamivir monotherapy in mice infected with influenza A (H1N1) pdm2009 virus. J. Med. Virol. 2017;89(12):2239–2243.</Citation><ArticleIdList><ArticleId IdType="pubmed">28792077</ArticleId></ArticleIdList></Reference><Reference><Citation>Ishaqui A.A., Khan A.H., Sulaiman S.A.S., Alsultan M.T., Khan I., Naqvi A.A. Assessment of efficacy of Oseltamivir-Azithromycin combination therapy in prevention of Influenza-A (H1N1) pdm09 infection complications and rapidity of symptoms relief. Expert Rev. Respir. Med. 2020;14(5):533–541.</Citation><ArticleIdList><ArticleId IdType="pubmed">32053044</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuhn J.H., Becker S., Ebihara H., Geisbert T.W., Johnson K.M., Kawaoka Y., Lipkin W.I., Negredo A.I., Netesov S.V., Nichol S.T., Palacios G., Peters C.J., Tenorio A., Volchkov V.E., Jahrling P.B. Proposal for a revised taxonomy of the family Filoviridae: classification, names of taxa and viruses, and virus abbreviations. Arch. Virol. 2010;155(12):2083–2103.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3074192</ArticleId><ArticleId IdType="pubmed">21046175</ArticleId></ArticleIdList></Reference><Reference><Citation>Dhama K., Karthik K., Khandia R., Chakraborty S., Munjal A., Latheef S.K., Kumar D., Ramakrishnan M.A., Malik Y.S., Singh R., Malik S., Singh R.K., Chaicumpa W. Advances in designing and developing vaccines, drugs, and therapies to counter Ebola virus. Front. Immunol. 2018;9:1803. (-)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6095993</ArticleId><ArticleId IdType="pubmed">30147687</ArticleId></ArticleIdList></Reference><Reference><Citation>Sanchez A., Kiley M.P., Holloway B.P., Auperin D.D. Sequence analysis of the Ebola virus genome: organization, genetic elements, and comparison with the genome of Marburg virus. Virus Res. 1993;29(3):215–240.</Citation><ArticleIdList><ArticleId IdType="pubmed">8237108</ArticleId></ArticleIdList></Reference><Reference><Citation>Feldmann H., Geisbert T.W. Ebola haemorrhagic fever. Lancet. 2011;377(9768):849–862.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3406178</ArticleId><ArticleId IdType="pubmed">21084112</ArticleId></ArticleIdList></Reference><Reference><Citation>Volchkova V.A., Klenk H.D., Volchkov V.E. Delta-peptide is the carboxy-terminal cleavage fragment of the nonstructural small glycoprotein sGP of Ebola virus. Virology. 1999;265(1):164–171.</Citation><ArticleIdList><ArticleId IdType="pubmed">10603327</ArticleId></ArticleIdList></Reference><Reference><Citation>Broadhurst M.J., Brooks T.J.G., Pollock N.R. Diagnosis of Ebola virus disease: past, present, and future. Clin. Microbiol. Rev. 2016;29(4):773–793.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5010747</ArticleId><ArticleId IdType="pubmed">27413095</ArticleId></ArticleIdList></Reference><Reference><Citation>Elshabrawy H.A., Erickson T.B., Prabhakar B.S. Ebola virus outbreak, updates on current therapeutic strategies. Rev. Med Virol. 2015;25(4):241–253.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7169053</ArticleId><ArticleId IdType="pubmed">25962887</ArticleId></ArticleIdList></Reference><Reference><Citation>Kabakli R. Ebola virus: an overview disease and treatment. Asian J. Pharm. Clin. Res. 2019;12:57–62.</Citation></Reference><Reference><Citation>Bixler S.L., Duplantier A.J., Bavari S. Discovering drugs for the treatment of Ebola virus. Curr. Treat. Options Infect. Dis. 2017;9(3):299–317.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5570806</ArticleId><ArticleId IdType="pubmed">28890666</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun W., He S., Martínez-Romero C., Kouznetsova J., Tawa G., Xu M., Shinn P., Fisher E., Long Y., Motabar O., Yang S., Sanderson P.E., Williamson P.R., García-Sastre A., Qiu X., Zheng W. Synergistic drug combination effectively blocks Ebola virus infection. Antivir. Res. 2017;137:165–172.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5182099</ArticleId><ArticleId IdType="pubmed">27890675</ArticleId></ArticleIdList></Reference><Reference><Citation>Madrid P.B., Panchal R.G., Warren T.K., Shurtleff A.C., Endsley A.N., Green C.E., Kolokoltsov A., Davey R., Manger I.D., Gilfillan L., Bavari S., Tanga M.J. Evaluation of Ebola virus inhibitors for drug repurposing. ACS Infect. Dis. 2015;1(7):317–326.</Citation><ArticleIdList><ArticleId IdType="pubmed">27622822</ArticleId></ArticleIdList></Reference><Reference><Citation>Du X., Zuo X., Meng F., Wu F., Zhao X., Li C., Cheng G., Qin F.X. Combinatorial screening of a panel of FDA-approved drugs identifies several candidates with anti-Ebola activities. Biochem. Biophys. Res. Commun. 2020;522(4):862–868.</Citation><ArticleIdList><ArticleId IdType="pubmed">31806372</ArticleId></ArticleIdList></Reference><Reference><Citation>Schögler A., Kopf B.S., Edwards M.R., Johnston S.L., Casaulta C., Kieninger E., Jung A., Moeller A., Geiser T., Regamey N., Alves M.P. Novel antiviral properties of azithromycin in cystic fibrosis airway epithelial cells. Eur. Respir. J. 2015;45(2):428–439.</Citation><ArticleIdList><ArticleId IdType="pubmed">25359346</ArticleId></ArticleIdList></Reference><Reference><Citation>Baz M., Boivin G. Antiviral agents in development for Zika virus infections. Pharmaceuticals. 2019;12(3):101.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6789597</ArticleId><ArticleId IdType="pubmed">31261947</ArticleId></ArticleIdList></Reference><Reference><Citation>Duffy M.R., Chen T.-H., Hancock W.T., Powers A.M., Kool J.L., Lanciotti R.S., Pretrick M., Marfel M., Holzbauer S., Dubray C., Guillaumot L., Griggs A., Bel M., Lambert A.J., Laven J., Kosoy O., Panella A., Biggerstaff B.J., Fischer M., Hayes E.B. Zika virus outbreak on Yap Island, federated states of Micronesia. NEJM. 2009;360(24):2536–2543.</Citation><ArticleIdList><ArticleId IdType="pubmed">19516034</ArticleId></ArticleIdList></Reference><Reference><Citation>Simpson D.I. Zika virus infection in man. Trans. R. Soc. Trop. Med. Hyg. 1964;58(4):335–338.</Citation><ArticleIdList><ArticleId IdType="pubmed">14175744</ArticleId></ArticleIdList></Reference><Reference><Citation>Musso D., Gubler D.J. Zika virus. Clin. Microbiol. Rev. 2016;29(3):487–524.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4861986</ArticleId><ArticleId IdType="pubmed">27029595</ArticleId></ArticleIdList></Reference><Reference><Citation>Li C., Zu S., Deng Y.-Q., Li D., Parvatiyar K., Quanquin N., Shang J., Sun N., Su J., Liu Z., Wang M., Aliyari S.R., Li X.F., Wu A., Ma F., Shi Y., Nielsen-Saines K., Jung J.U., Qin F.X.F., Qin C.F., Cheng G. Azithromycin protects against Zika virus infection by upregulating virus-induced type I and III interferon responses. Antimicrob. Agents Chemother. 2019;63(12) e00394-19.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6879226</ArticleId><ArticleId IdType="pubmed">31527024</ArticleId></ArticleIdList></Reference><Reference><Citation>Oliver M.E., Hinks T.S. Azithromycin in viral infections. Rev. Med. Virol. 2021;31(2)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7536932</ArticleId><ArticleId IdType="pubmed">32969125</ArticleId></ArticleIdList></Reference><Reference><Citation>Retallack H., Di Lullo E., Arias C., Knopp K.A., Laurie M.T., Sandoval-Espinosa C., Mancia Leon W.R., Krencik R., Ullian E.M., Spatazza J., Pollen A.A., Mandel-Brehm C., Nowakowski T.J., Kriegstein A.R., DeRisi J.L. Zika virus cell tropism in the developing human brain and inhibition by azithromycin. PNAS. 2016;113(50):14408–14413.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5167169</ArticleId><ArticleId IdType="pubmed">27911847</ArticleId></ArticleIdList></Reference><Reference><Citation>Savidis G., Perreira J.M., Portmann J.M., Meraner P., Guo Z., Green S., Brass A.L. The IFITMs inhibit Zika virus replication. Cell Rep. 2016;15(11):2323–2330.</Citation><ArticleIdList><ArticleId IdType="pubmed">27268505</ArticleId></ArticleIdList></Reference><Reference><Citation>Daniels B.P., Kofman S.B., Smith J.R., Norris G.T., Snyder A.G., Kolb J.P., Gao X., Locasale J.W., Martinez J., Gale M., Loo Y.M., Oberst A. The nucleotide sensor ZBP1 and kinase RIPK3 induce the enzyme IRG1 to promote an antiviral metabolic state in neurons. Immunity. 2019;50(1):64–76. e4.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6342485</ArticleId><ArticleId IdType="pubmed">30635240</ArticleId></ArticleIdList></Reference><Reference><Citation>Renna M., Schaffner C., Brown K., Shang S., Tamayo M.H., Hegyi K., Grimsey N.J., Cusens D., Coulter S., Cooper J., Bowden A.R., Newton S.M., Kampmann B., Helm J., Jones A., Haworth C.S., Basaraba R.J., DeGroote M.A., Ordway D.J., Rubinsztein D.C., Floto R.A. Azithromycin blocks autophagy and may predispose cystic fibrosis patients to mycobacterial infection. J. Clin. Investig. 2011;121(9):3554–3563.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3163956</ArticleId><ArticleId IdType="pubmed">21804191</ArticleId></ArticleIdList></Reference><Reference><Citation>Bosseboeuf E., Aubry M., Nhan T., de Pina J.J., Rolain J.M., Raoult D., Musso D. Azithromycin inhibits the replication of Zika virus. J. Antivir. Antiretrovir. 2018;10(1):6–11.</Citation></Reference><Reference><Citation>Bitnun A., Allen U., Heurter H., King S.M., Opavsky M.A., Ford-Jones E.L., Matlow A., Kitai I., Tellier R., Richardson S., Manson D., Babyn P., Read S. Children hospitalized with severe acute respiratory syndrome-related illness in Toronto. Pediatrics. 2003;112(4)</Citation><ArticleIdList><ArticleId IdType="pubmed">14523209</ArticleId></ArticleIdList></Reference><Reference><Citation>Gillim-Ross L., Subbarao K. Emerging respiratory viruses: challenges and vaccine strategies. Clin. Microbiol. Rev. 2006;19(4):614–636.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1592697</ArticleId><ArticleId IdType="pubmed">17041137</ArticleId></ArticleIdList></Reference><Reference><Citation>Christian M.D., Poutanen S.M., Loutfy M.R., Muller M.P., Low D.E. Severe acute respiratory syndrome. Clin. Infect. Dis. 2004;38(10):1420–1427.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7107873</ArticleId><ArticleId IdType="pubmed">15156481</ArticleId></ArticleIdList></Reference><Reference><Citation>Akaji K., Konno H. Design and evaluation of anti-SARS-coronavirus agents based on molecular interactions with the viral protease. Molecules. 2020;25(17):3920.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7504761</ArticleId><ArticleId IdType="pubmed">32867349</ArticleId></ArticleIdList></Reference><Reference><Citation>Hasoksuz M., Alekseev K., Vlasova A., Zhang X., Spiro D., Halpin R., Wang S., Ghedin E., Saif L.J. Biologic, antigenic, and full-length genomic characterization of a bovine-like coronavirus isolated from a giraffe. J. Virol. 2007;81(10):4981–4990.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1900194</ArticleId><ArticleId IdType="pubmed">17344285</ArticleId></ArticleIdList></Reference><Reference><Citation>Lau S.K., Woo P.C., Yip C.C., Tse H., Tsoi H.W., Cheng V.C., Lee P., Tang B.S., Cheung C.H., Lee R.A., So L.Y., Lau Y.L., Chan K.H., Yuen K.Y. Coronavirus HKU1 and other coronavirus infections in Hong Kong. J. Clin. Microbiol. 2006;44(6):2063–2071.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1489438</ArticleId><ArticleId IdType="pubmed">16757599</ArticleId></ArticleIdList></Reference><Reference><Citation>Li W., Shi Z., Yu M., Ren W., Smith C., Epstein J.H., Wang H., Crameri G., Hu Z., Zhang H., Zhang J., McEachern J., Field H., Daszak P., Eaton B.T., Zhang S., Wang L.F. Bats are natural reservoirs of SARS-like coronaviruses. Science. 2005;310(5748):676–679.</Citation><ArticleIdList><ArticleId IdType="pubmed">16195424</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiang S., He Y., Liu S. SARS vaccine development. Emerg. Infect. Dis. 2005;11(7):1016–1020.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3371787</ArticleId><ArticleId IdType="pubmed">16022774</ArticleId></ArticleIdList></Reference><Reference><Citation>Tyrrell D.A., Bynoe M.L. Cultivation of viruses from a high proportion of patients with colds. Lancet. 1966;1(7428):76–77.</Citation><ArticleIdList><ArticleId IdType="pubmed">4158999</ArticleId></ArticleIdList></Reference><Reference><Citation>Hamre D., Procknow J.J. A new virus isolated from the human respiratory tract. Proc. Soc. Exp. Biol. Med. 1966;121(1):190–193.</Citation><ArticleIdList><ArticleId IdType="pubmed">4285768</ArticleId></ArticleIdList></Reference><Reference><Citation>Weiss S.R., Navas-Martin S. Coronavirus pathogenesis and the emerging pathogen severe acute respiratory syndrome coronavirus. Microbiol. Mol. Biol. Rev. 2005;69(4):635–664.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1306801</ArticleId><ArticleId IdType="pubmed">16339739</ArticleId></ArticleIdList></Reference><Reference><Citation>Chany C., Moscovici O., Lebon P., Rousset S. Association of coronavirus infection with neonatal necrotizing enterocolitis. Pediatrics. 1982;69(2):209–214.</Citation><ArticleIdList><ArticleId IdType="pubmed">6276855</ArticleId></ArticleIdList></Reference><Reference><Citation>Stadler K., Masignani V., Eickmann M., Becker S., Abrignani S., Klenk H.D., Rappuoli R. SARS--beginning to understand a new virus. Nat. Rev. Microbiol. 2003;1(3):209–218.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7097337</ArticleId><ArticleId IdType="pubmed">15035025</ArticleId></ArticleIdList></Reference><Reference><Citation>Hui D.S.C., Zumla A. Severe Acute Respiratory Syndrome: historical, epidemiologic, and clinical features. Infect. Dis. Clin. North Am. 2019;33(4):869–889.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7127569</ArticleId><ArticleId IdType="pubmed">31668196</ArticleId></ArticleIdList></Reference><Reference><Citation>Oliver M.E., Hinks T.S.C. Azithromycin in viral infections. Rev. Med. Virol. 2021;31(2)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7536932</ArticleId><ArticleId IdType="pubmed">32969125</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao Z. Description and clinical treatment of an early outbreak of severe acute respiratory syndrome (SARS) in Guangzhou, PR China. J. Med. Microbiol. 2003;52(Pt 8):715–720.</Citation><ArticleIdList><ArticleId IdType="pubmed">12867568</ArticleId></ArticleIdList></Reference><Reference><Citation>Payne S. Family coronaviridae. Viruses. 2017:149–158.</Citation><ArticleIdList><ArticleId IdType="pubmed">0</ArticleId></ArticleIdList></Reference><Reference><Citation>Jungreis I., Nelson C.W., Ardern Z., Finkel Y., Krogan N.J., Sato K., Ziebuhr J., Stern-Ginossar N., Pavesi A., Firth A.E., Gorbalenya A.E., Kellis M. Conflicting and ambiguous names of overlapping ORFs in the SARS-CoV-2 genome: a homology-based resolution. Virology. 2021;558:145–151.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7967279</ArticleId><ArticleId IdType="pubmed">33774510</ArticleId></ArticleIdList></Reference><Reference><Citation>Podder S., Ghosh A., Ghosh T. Mutations in membrane‐fusion subunit of spike glycoprotein play crucial role in the recent outbreak of COVID‐19. J. Med. Virol. 2021;93(5):2790–2798.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7675664</ArticleId><ArticleId IdType="pubmed">33090493</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang M.-Y., Zhao R., Gao L.-J., Gao X.-F., Wang D.-P., Cao J.-M. SARS-CoV-2: structure, biology, and structure-based therapeutics development. Front. Cell. Infect. Microbiol. 2020;10(724)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7723891</ArticleId><ArticleId IdType="pubmed">33324574</ArticleId></ArticleIdList></Reference><Reference><Citation>Benton D.J., Wrobel A.G., Xu P., Roustan C., Martin S.R., Rosenthal P.B., Skehel J.J., Gamblin S.J. Receptor binding and priming of the spike protein of SARS-CoV-2 for membrane fusion. Nature. 2020;588(7837):327–330.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7116727</ArticleId><ArticleId IdType="pubmed">32942285</ArticleId></ArticleIdList></Reference><Reference><Citation>Singh A., Steinkellner G., Köchl K., Gruber K., Gruber C.C. Serine 477 plays a crucial role in the interaction of the SARS-CoV-2 spike protein with the human receptor ACE2. Sci. Rep. 2021;11(1):4320.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7900180</ArticleId><ArticleId IdType="pubmed">33619331</ArticleId></ArticleIdList></Reference><Reference><Citation>Cure M.C., Kucuk A., Cure E. Colchicine may not be effective in COVID-19 infection; it may even be harmful? Clin. Rheumatol. 2020;39(7):2101–2102.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7213772</ArticleId><ArticleId IdType="pubmed">32394215</ArticleId></ArticleIdList></Reference><Reference><Citation>Nujić K., Banjanac M., Munić V., Polančec D., Haber V.E. Impairment of lysosomal functions by azithromycin and chloroquine contributes to anti-inflammatory phenotype. Cell. Immunol. 2012;279(1):78–86.</Citation><ArticleIdList><ArticleId IdType="pubmed">23099154</ArticleId></ArticleIdList></Reference><Reference><Citation>Fantini J., Chahinian H., Yahi N. Synergistic antiviral effect of hydroxychloroquine and azithromycin in combination against SARS-CoV-2: what molecular dynamics studies of virus-host interactions reveal. Int. J. Antimicrob. Agents. 2020;56(2)</Citation><ArticleIdList><ArticleId IdType="pubmed">32862840</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu C., Zheng M., Yang Y., Gu X., Yang K., Li M., Liu Y., Zhang Q., Zhang P., Wang Y., Wang Q., Xu Y., Zhou Y., Zhang Y., Chen L., Li H. Furin: a potential therapeutic target for COVID-19. Iscience. 2020;23(10)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7534598</ArticleId><ArticleId IdType="pubmed">33043282</ArticleId></ArticleIdList></Reference><Reference><Citation>J.F. Poschet , E.A. Perkett , G.S. Timmins , V. Deretic , Azithromycin and ciprofloxacin have a chloroquine-like effect on respiratory epithelial cells, BioRxiv, 2020.</Citation></Reference><Reference><Citation>Echeverría-Esnal D., Martin-Ontiyuelo C., Navarrete-Rouco M.E., De-Antonio Cuscó M., Ferrández O., Horcajada J.P., Grau S. Azithromycin in the treatment of COVID-19: a review. Expert Rev. Anti Infect. Ther. 2021;19(2):147–163.</Citation><ArticleIdList><ArticleId IdType="pubmed">32853038</ArticleId></ArticleIdList></Reference><Reference><Citation>Venditto V.J., Haydar D., Abdel-Latif A., Gensel J.C., Anstead M.I., Pitts M.G., Creameans J., Kopper T.J., Peng C., Feola D.J. Immunomodulatory effects of azithromycin revisited: potential applications to COVID-19. Front. Immunol. 2021;12:285.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7906979</ArticleId><ArticleId IdType="pubmed">33643308</ArticleId></ArticleIdList></Reference><Reference><Citation>Touret F., Gilles M., Barral K., Nougairède A., van Helden J., Decroly E., de Lamballerie X., Coutard B. In vitro screening of a FDA approved chemical library reveals potential inhibitors of SARS-CoV-2 replication. Sci. Rep. 2020;10(1):13093.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7403393</ArticleId><ArticleId IdType="pubmed">32753646</ArticleId></ArticleIdList></Reference><Reference><Citation>Andreani J., Le Bideau M., Duflot I., Jardot P., Rolland C., Boxberger M., Wurtz N., Rolain J.M., Colson P., La Scola B., Raoult D. In vitro testing of combined hydroxychloroquine and azithromycin on SARS-CoV-2 shows synergistic effect. Microb. Pathog. 2020;145</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7182748</ArticleId><ArticleId IdType="pubmed">32344177</ArticleId></ArticleIdList></Reference><Reference><Citation>Furtado R., Berwanger O., Fonseca H.A., Corrêa T.D., Ferraz L.R., Lapa M.G., Zampieri F.G., Veiga V.C., Azevedo L., Rosa R.G., Lopes R.D., Avezum A., Manoel A., Piza F., Martins P.A., Lisboa T.C., Pereira A.J., Olivato G.B., Dantas V., Milan E.P., Gebara O., Amazonas R.B., Oliveira M.B., Soares R., Moia D., Piano L., Castilho K., Momesso R., Schettino G., Rizzo L.V., Neto A.S., Machado F.R., Cavalcanti A.B., COALITION COVID- Brazil II I. Azithromycin in addition to standard of care versus standard of care alone in the treatment of patients admitted to the hospital with severe COVID-19 in Brazil (COALITION II): a randomised clinical trial. Lancet. 2020;396(10256):959–967.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7836431</ArticleId><ArticleId IdType="pubmed">32896292</ArticleId></ArticleIdList></Reference><Reference><Citation>RECOVERY Collaborative G. Azithromycin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet. 2021;397(10274):605–612.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7884931</ArticleId><ArticleId IdType="pubmed">33545096</ArticleId></ArticleIdList></Reference><Reference><Citation>Egorova A., Ekins S., Schmidtke M., Makarov V. Back to the future: advances in development of broad-spectrum capsid-binding inhibitors of enteroviruses. Eur. J. Med. Chem. 2019;178:606–622.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8194503</ArticleId><ArticleId IdType="pubmed">31226653</ArticleId></ArticleIdList></Reference><Reference><Citation>Jacobs S.E., Lamson D.M., St, George K., Walsh T.J. Human rhinoviruses. Clin. Microbiol. Rev. 2013;26(1):135–162.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3553670</ArticleId><ArticleId IdType="pubmed">23297263</ArticleId></ArticleIdList></Reference><Reference><Citation>Ylä-Pelto J., Tripathi L., Susi P. Therapeutic use of native and recombinant enteroviruses. Viruses. 2016;8(3):57.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4810247</ArticleId><ArticleId IdType="pubmed">26907330</ArticleId></ArticleIdList></Reference><Reference><Citation>Zeng S., Meng X., Huang Q., Lei N., Zeng L., Jiang X., Guo X. Spiramycin and azithromycin, safe for administration to children, exert antiviral activity against enterovirus A71 in vitro and in vivo. Int. J. Antimicrob. Agents. 2019;53(4):362–369.</Citation><ArticleIdList><ArticleId IdType="pubmed">30599241</ArticleId></ArticleIdList></Reference><Reference><Citation>Stokholm J., Chawes B.L., Vissing N.H., Bjarnadóttir E., Pedersen T.M., Vinding R.K., Schoos A.M., Wolsk H.M., Thorsteinsdóttir S., Hallas H.W., Arianto L., Schjørring S., Krogfelt K.A., Fischer T.K., Pipper C.B., Bønnelykke K., Bisgaard H. Azithromycin for episodes with asthma-like symptoms in young children aged aged 1-3 years: a randomised, double-blind, placebo-controlled trial. Lancet Respir. Med. 2016;4(1):19–26.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7164820</ArticleId><ArticleId IdType="pubmed">26704020</ArticleId></ArticleIdList></Reference><Reference><Citation>Praharaj I., Parker E.P.K., Giri S., Allen D.J., Silas S., Revathi R., Kaliappan S.P., John J., Prasad J.H., Kampmann B., Iturriza-Gómara M., Grassly N.C., Kang G. Influence of nonpolio enteroviruses and the bacterial gut microbiota on oral poliovirus vaccine response: a study from South India. J. Infect. Dis. 2018;219(8):1178–1186.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6601701</ArticleId><ArticleId IdType="pubmed">30247561</ArticleId></ArticleIdList></Reference><Reference><Citation>Schögler A., Kopf B.S., Edwards M.R., Johnston S.L., Casaulta C., Kieninger E., Jung A., Moeller A., Geiser T., Regamey N., Alves M.P. Novel antiviral properties of azithromycin in cystic fibrosis airway epithelial cells. Eur. Respir. J. 2015;45(2):428–439.</Citation><ArticleIdList><ArticleId IdType="pubmed">25359346</ArticleId></ArticleIdList></Reference><Reference><Citation>Ling K.-M., Hillas J., Lavender M.A., Wrobel J.P., Musk M., Stick S.M., Kicic A. Azithromycin reduces airway inflammation induced by human rhinovirus in lung allograft recipients. Respirology. 2019;24(12):1212–1219.</Citation><ArticleIdList><ArticleId IdType="pubmed">30989728</ArticleId></ArticleIdList></Reference><Reference><Citation>Menzel M., Akbarshahi H., Tufvesson E., Persson C., Bjermer L., Uller L. Azithromycin augments rhinovirus-induced IFNβ via cytosolic MDA5 in experimental models of asthma exacerbation. Oncotarget. 2017;8(19):31601–31611.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5458233</ArticleId><ArticleId IdType="pubmed">28415826</ArticleId></ArticleIdList></Reference><Reference><Citation>Gielen V., Johnston S.L., Edwards M.R. Azithromycin induces anti-viral responses in bronchial epithelial cells. Eur. Respir. J. 2010;36(3):646–654.</Citation><ArticleIdList><ArticleId IdType="pubmed">20150207</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>